

The Green Organic Dutchman Holdings Ltd.
Unaudited Interim Condensed Consolidated Financial Statements
For the three and six months ended June 30, 2021 and June 30, 2020

The Green Organic Dutchman Holdings Ltd. INTERIM CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

(Unaudited)

(expressed in thousands of Canadian dollars, except common shares outstanding)

-	Notes		As at June 30, 2021	As at December 31, 2020
ASSETS				
Current assets				
Cash and cash equivalents		\$	8,275 \$	11,212
Restricted cash	17		717	622
Refundable sales taxes receivable			213	160
Trade receivables	17		9,134	10,023
Biological assets	9		2,652	1,984
Inventories	10		20,727	17,135
Prepaid expenses and deposits			1,750	1,641
Other current assets	11		1,392	853
Deferred financing costs		\$	298 45,158 \$	750 44,380
Non-current assets		Φ	45,156	44,360
Property, plant and equipment	7		116,633	147,263
Intangible assets	8		11,868	8,933
Other assets	11, 16		3,852	10,999
	,			· · · · · · · · · · · · · · · · · · ·
Total assets		\$	177,511 \$	211,575
LIABILITIES AND SHAREHOLDERS' EQUITY				
Current liabilities				
Accounts payable and accrued liabilities		\$	17,317 \$	24,453
Sales taxes payable			294	-
Deferred revenue			_	150
Loans	6		15,732	40,755
Current portion of lease liabilities	12		2,000	1,019
Non-current liabilities			35,343	66,377
Lease liabilities	12		5,145	4,551
Contingent consideration			´ –	39
Deferred tax liability			615	804
,			5,760	5,394
Total liabilities		\$	41,103 \$	71,771
Shareholders' equity				
Share capital	13		485,974	468,379
Contributed surplus	14		108,803	108,874
Deficit			(456,501)	(436,559
Reserve for foreign currency translations			(1,089)	255
Total Shareholders' Equity attributed to The Green Organic Dutchman				
Holdings Ltd.		\$	137,187 \$	140,949
Non-controlling interests			(779)	(1,145
Total Shareholders' Equity			136,408	139,804
Total Liabilities and Shareholders' Equity		\$	177,511 \$	211,575
Total number of common shares outstanding			529,143,756	486,675,760
C-i	2			
Going concern	2 16			
Commitments and contingencies	10			

The accompanying notes are an integral part of these interim condensed consolidated financial statements.

The Green Organic Dutchman Holdings Ltd. INTERIM CONDENSED CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS

(Unaudited) (expressed in thousands of Canadian Dollars, except per share amounts)

(Ondiduted) (expressed in inousands of Candalan Do	itters, est	cepi	•	months ended	For the six mo	onths andod
	Notes		June 30, 2021	June 30, 2020	June 30, 2021	June 30, 2020
Revenue		\$	11,816	\$ 4,825	\$ 20,798 \$	7,884
Excise duties		Ψ	(2,294)	(403)	(3,573)	(531
Net revenue		-	9,522	4,422	17,225	7,353
Cost of sales			6,256	4,028	12,620	5,944
Gross profit before change in fair value of biological			0,200	.,,,20		
assets			3,266	394	4,605	1,409
Realized fair value adjustment on sale of inventory			(2,331)	(1,821)	(3,861)	(2,366
Unrealized gain on changes in fair value of biological assets	9		2,244	2,753	5,565	3,989
Gross profit		\$	3,179	\$ 1,326	\$ 6,309 \$	3,032
Operating expenses						
Sales and marketing expenses		\$	1,337	\$ 2,240	\$ 2,738 \$	4,703
Research and development expenses			181	319	648	839
General and administrative expenses			5,743	5,710	10,298	15,502
Share based compensation	14		1,019	1,657	1,632	4,127
Depreciation and amortization	7, 8		3,979	1,281	5,966	3,000
Total operating expenses		\$	12,259	\$ 11,207	\$ 21,282 \$	28,171
Loss from operations			(9,080)	(9,881)	(14,973)	(25,139
Foreign exchange gain (loss)	17[c]		190	785	400	(1,729
Finance costs			(2,445)	(877)	(4,347)	(1,016
Accretion expense	6		(3,571)	(250)	(4,853)	(250
Finance income			50	98	102	269
Share of loss on investments in associates			_	_	_	(148
Revaluation of contingent consideration			_	92	39	361
Gain (loss) on disposal of assets	7		(100)	76	110	44
Impairment of investment in associates			`—	_	_	(3,082
Reversal of impairment / (impairment) charge for non-	7, 8				21.011	(50.765
financial assets				_	21,811	(52,765
Loss on derecognition on investment in joint venture	_		(17.600)	_	(761)	_
Loss on assets held for sale Debt modification	5		(17,688)	(33)	(17,688)	(33
			(22.211)		(20.170)	
Loss before income taxes			(32,644)	(9,990)	(20,160)	(83,488
Deferred income tax recovery (expense)			164	215	143	277
Net loss		\$ _	(32,480)	\$ (9,775)	\$ (20,017) \$	(83,211
Other comprehensive (income)/loss						
Foreign currency translation (income)/loss Foreign currency translation income on equity method			45	471	1,349	(1,369
investment			_	(202)		(708
Comprehensive loss		\$	(32,525)	\$(10,044)	\$ (21,366) \$	(81,134
Net loss attributable to:						
The Green Organic Dutchman Holdings Ltd.			(32,460)	(9,655)	(19,942)	(82,806
Non-controlling interests			(20)		(75)	(405
Comprehensive loss attributable to:						
The Green Organic Dutchman Holdings Ltd.			(32,505)	(9,924)	(21,291)	(80,729
			(20)		(75)	(405
Non-controlling interests			(20)	(120)		(.05
			(20)	(120)		(100
		\$	(0.06)		(0.04) \$	(0.25

The accompanying notes are an integral part of these interim condensed consolidated financial statements.

The Green Organic Dutchman Holdings Ltd. INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY

(Unaudited)

(expressed in thousands of Canadian Dollars, except number of shares)

		Share C	apital			Contribut	ed Surplus						
	Notes	Common Shares	Amount	Reserve for share based payments	Reserve for warrants	Other contributed surplus	Escrowed share units	Shares to be issued	Total Contributed surplus	Reserve for foreign currency translations	Accumulated deficit	Non- Controlling Interests	Total
		#	\$	\$	\$	\$	\$	\$	\$	\$	\$	\$	\$
Balance at December 31, 2020		486,675,760	468,379	23,258	66,111	11,129	7,972	404	108,874	255	(436,559)	(1,145)	139,804
Issuance of common shares	13[i]	14,341,958	7,655	_	_	_	_	_	-	_	_	_	7,655
Share based compensation	14[a,c]	_	_	613	_	_	_	_	613	_	_	_	613
Exercise of warrants	13[ii]	24,198,600	8,684	_	(1,124)	_	_	_	(1,124)	_	_	_	7,560
Expiry of stock options	14[a]	_	_	(4,102)	_	4,102	_	_	-	_	_	_	-
Expiry of warrants	14[b]	_	_	_	(37,638)	37,638	_	_	-	_	_	_	-
Restricted share units exercised during	13[iii]	200.010	155	(185)					(185)				
period	1051 1	390,810	175	(175)	_	_	_	_	(175)	_	_	_	-
Shares issued in connection with accounts payable	13[iv]	1,591,535	404	_	_	_	_	(104)	(104)	_	_	_	300
Comprehensive income		_	_	_	_	_	_	_	-	(1,304)	12,518	(55)	11,159
Elimination of non-controlling interest													
on disposal of Denmark										5		441	446
Balance at March 31, 2021		527,198,663	485,297	19,594	27,349	52,869	7,972	300	108,084	(1,044)	(424,041)	(759)	167,537
Issuance of common shares	13[i]	1,073,000	377	_	_	_	_	_	-	_	_	_	377
Share based compensation	14[a,c]	_	_	1,019	_	_	_	_	1,019	_	_	_	1,019
Expiry of warrants	14[b]	_	_	_	(17,243)	17,243	_	_	-	_	_	_	-
Shares issued in connection with	13[iv]												
accounts payable		872,093	300	_	_	_	_	(300)	(300)	_	_	_	-
Comprehensive income										(45)	(32,460)	(20)	(32,525)
Balance at June 30, 2021		<u>529,143,756</u>	485,974	20,613	10,106	70,112	7,972		108,803	(1,089)	(456,501)	(779)	136,408

		Share C	apital			Contribut	ed Surplus						
	Notes	Common Shares	Amount	Reserve for share based payments	Reserve for warrants	Other contributed surplus	Escrowed share units	Shares to be issued	Total Contributed surplus	Reserve for foreign currency translations	Accumulated deficit	Non- Controlling Interests	Total
		#	\$	\$	\$	\$	\$	\$	\$	\$	\$	\$	\$
Balance at December 31, 2019		312,733,244	428,651	22,247	64,415	1,129	7,972		95,763	(2,241)	(254,018)	(555)	267,600
Share based compensation		_	15	2,205	_	_	_	_	2,205	_	_	_	2,220
Exercise of stock options		847,600	763	(339)	_	_	_	_	(339)	_	_	_	424
Exercise of warrants		500	1	_	_	_	_	_	_	_	_	_	1
Expiry of options		_	_	(272)	_	272	_	_	_	_	_	_	-
Restricted share units exercised during period		27,174	75	(75)	_	_	_	_	(75)	_	_	_	_
Shares to be issued		_	_		_	_	_	1,876	1,876	_	_	_	1,876
Comprehensive loss		_	_	_	_	_	_	_	_	2,346	(73,151)	(285)	(71,090)
Balance at March 31, 2020		313,608,518	429,505	23,766	64,415	1,401	7,972	1,876	99,430	105	(327,169)	(840)	201,031
Bought deal offerings		63,661,700	16,220	_	4,533			_	4,533		_	_	20,753
Share based compensation		_	8	1,649	_	_	_	_	1,649	_	_	_	1,657
Warrants issued in connection with debt		_	_	_	621	_	_	_	621	_	_	_	621
Exercise of warrants		500,000	221	_	(31)	_	_	_	(31)	_	_	_	190
Expiry of warrants		_	_	_	(8,150)	8,150	_	_	_	_	_	_	-
Expiry of options		_	_	(648)	_	648	_	_	_	_	_	_	-
Convertible shares issued		24,691	_	_	_	_	_	_	_	_	_	_	-
Shares issued in connection with													
accounts payable		6,858,375	1,876	_	_	_	_	(1,876)	(1,876)	_	_	_	-
Comprehensive loss										(269)	(9,655)	(120)	(10,044)
Balance at June 30, 2020		384,653,284	447,830	24,767	61,388	10,199	7,972		104,326	(164)	(336,824)	(960)	214,208

An unlimited number of common shares are authorized for issue.

The accompanying notes are an integral part of these interim condensed consolidated financial statements.

The Green Organic Dutchman Holdings Ltd. INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

(expressed in thousands of Canadian dollars)

OPERATING ACTIVITIES Net loss \$ (32,480) \$ (9,775) \$ (20,017) \$ Items not affecting cash: (Reversal of impairment) / Impairment of property, plant and equipment — — — (17,765) (Reversal of impairment) / Impairment of intangible assets 8 — — — (4,046) Loss on assets held for sale 5 17,688 — 17,688 Impairment of investment in associates — — — Share based compensation 14 1,019 1,657 1,632 Depreciation of property, plant and equipment 7 3,529 958 5,176 Amortization of intangible assets 8 450 323 790	(83,211) 51,725 1,040 — 3,082 4,127
Net loss \$ (32,480) \$ (9,775) \$ (20,017) \$ Items not affecting cash: (Reversal of impairment) / Impairment of property, plant and equipment (Reversal of impairment) / Impairment of intangible assets (Reversal of impairment) / Impairment of intangible assets 8 - - 4,046) Loss on assets held for sale	51,725 1,040 — 3,082
Items not affecting cash: (Reversal of impairment) / Impairment of property, plant and equipment 7 — — — (17,765) (Reversal of impairment) / Impairment of intangible assets 8 — — — (4,046) Loss on assets held for sale 5 17,688 — 17,688 Impairment of investment in associates — — — Share based compensation 14 1,019 1,657 1,632 Depreciation of property, plant and equipment 7 3,529 958 5,176	51,725 1,040 — 3,082
(Reversal of impairment) / Impairment of property, plant and equipment 7 — — (17,765) (Reversal of impairment) / Impairment of intangible assets 8 — — (4,046) Loss on assets held for sale 5 17,688 — 17,688 Impairment of investment in associates — — — Share based compensation 14 1,019 1,657 1,632 Depreciation of property, plant and equipment 7 3,529 958 5,176	1,040 — 3,082
(Reversal of impairment) / Impairment of intangible assets 8 — — (4,046) Loss on assets held for sale 5 17,688 — 17,688 Impairment of investment in associates — — — Share based compensation 14 1,019 1,657 1,632 Depreciation of property, plant and equipment 7 3,529 958 5,176	3,082
Loss on assets held for sale 5 17,688 — 17,688 Impairment of investment in associates — — — Share based compensation 14 1,019 1,657 1,632 Depreciation of property, plant and equipment 7 3,529 958 5,176	3,082
Impairment of investment in associates———Share based compensation141,0191,6571,632Depreciation of property, plant and equipment73,5299585,176	
Share based compensation 14 1,019 1,657 1,632 Depreciation of property, plant and equipment 7 3,529 958 5,176	4.127
Depreciation of property, plant and equipment 7 3,529 958 5,176	
	2,221
	779
Realized fair value adjustment on sale of inventory 2,331 1,821 3,861	2,366
Unrealized gain on change in fair value of biological assets 9 (2,244) (2,753) (5,565)	(3,989)
Accretion 6 3,571 250 4,853	250
Share of loss on investments in associates — — — —	148
Revaluation of contingent consideration — (92) (39)	(361)
Loss (gain) on disposal of assets 7 100 (76) (110)	(44)
Loss on derecognition on investment in joint venture — 761	_
Deferred financing costs expensed 227 276 452	276
Deferred income tax recovery (164) (215) (143)	(277)
Debt modification 6 — 33 —	33
Income taxes paid — (14) —	(14)
Changes in non-cash operating working capital items 15 174 (678) 1,136	467
Net cash used in operating activities \$(5,799) \$(8,285) \$(11,336) \$	(21,382)
INVESTING ACTIVITIES	
Additions to property, plant and equipment 7 (1,810) (10,574) (6,018)	(36,109)
Net proceeds from the disposition of the Valleyfield Assets 5 25,512 — 25,512	_
Net cash inflow on deposits 11 5,761 — 5,761	
Proceeds on disposal of assets 7 427 — 1,089	_
Transfer (to) from restricted cash (458) — (95)	8,359
Advances to related parties, net of repayments — 727 —	978
Net cash inflow on sale of investment 11 — — 1,242	(225)
Additions to intangible assets 8 (6) (225) (6)	(225)
Net cash proceeds (used) in investing activities \$ \$ \$ \$	(26,997)
FINANCING ACTIVITIES	
Proceeds from issuance of shares and warrants, net of share issue 377 20,753 8,032	20,753
costs 13 377 20,755 6,652	
Proceeds from issuance of debt, net of issue costs 6 — 12,351 —	19,009
Proceeds from the exercise of stock options and warrants 13,14 — 190 7,560	615
Interest received 21 20 40	144
Interest paid on lease liabilities 12 (115) (254)	(248)
Interest paid on debt 5 (1,790) (1,101) (3,329)	(1,621)
Principal payments of lease liabilities 12 (135) (87)	(169)
Principal payments of debt 6 (31,513) — (32,200)	
Change in balance of revolver facility 6 1,401 2,346	_
Net cash provided (used) in financing activities \$(31,754) \$ \$ 32,011 \$ (18,103) \$	38,483
Net cash inflow (outflow) \$ (8,127) \$ 13,654 \$ (1,954) \$	(9,896)
Net effects of foreign exchange (117) 276 (983)	1,104
Cash, beginning of period 16,519 4,847 11,212	27,569
Cash and cash equivalents, end of period \$ 8,275 \$ 18,777 \$ 8,275 \$	18,777

 $\label{thm:companying} \textit{ notes are an integral part of these interim condensed consolidated financial statements}.$

(Unaudited)

(expressed in thousands of Canadian Dollars except as otherwise indicated)

1. NATURE OF ACTIVITIES

The Green Organic Dutchman Holdings Ltd. ("TGODH" or the "Company") was incorporated on November 16, 2016, under the *Canada Business Corporations Act* ("CBCA"). The Company is a reporting issuer domiciled in Canada whose shares and certain warrants are publicly traded on the Toronto Stock Exchange ("TSX") under the symbol "TGOD" and on the OTCQX under the symbol "TGODF". The Company also has four classes of warrants listed on the TSX under the symbols "TGOD.WS", "TGOD.WR", "TGOD.WA" and "TGOD.WB". The Company's registered and head office is located at 6205 Airport Road, Building A – Suite 200, Mississauga, ON, L4V 1E3. These unaudited interim condensed consolidated financial statements for the three and six months ended June 30, 2021 and June 30, 2020 ("Interim Consolidated Financial Statements") include the financial statements of The Green Organic Dutchman Holdings Ltd. and its subsidiaries from the date the Company gained control of each subsidiary.

The Company's wholly-owned Canadian subsidiaries, The Green Organic Dutchman Ltd. ("TGOD") and Medican Organic Inc. ("Medican") are licensed producers under the *Cannabis Act* (Canada) and hold licences to produce cannabis plants, cannabis plant seeds, dried cannabis, fresh cannabis, cannabis oils, cannabis topicals, cannabis extracts and edible cannabis and, with respect to The Green Organic Dutchman Ltd. only, sell such cannabis products within Canada to provincially authorized retailers or distributors and federally licensed entities. The Company owns a cannabis cultivation facility near Hamilton, Ontario (the "Hamilton Facility"). The Company also operates out of another facility located in Valleyfield, Québec (the "Quebec Facility").

In addition to its Canadian operations, the Company, through its subsidiaries and strategic investments, is pursuing an international growth strategy, including through a hemp extraction business in Poland. The Company has established other strategic partnerships for the distribution of cannabis and hemp-derived medical products in Mexico, Germany, and other countries as regulations allow.

The outbreak of the novel strain of the coronavirus, SARS-COV-2 ("COVID-19"), and its eventual declaration as a pandemic by the World Health Organization ("WHO") on March 11, 2020 has resulted in governments worldwide enacting emergency measures to combat the spread of the virus. These measures have caused material disruption to businesses globally resulting in an economic slowdown. The Company implemented measures to protect its global workforce from COVID-19 and endeavouring to mitigate any long-term impact of the pandemic on its business which remain unknown. While it is difficult to predict the impact of COVID-19 on the Company's business, the Company continues to seek to mitigate these impacts through various means including engagement with its retailers, transition of its staff to working remotely where possible, increasing safety protocols and sanitation measures within the workplace, and monitoring developments in order to adapt and respond in order to protect the health and safety of the Company's employees and the best interests of the Company.

2. BASIS OF PRESENTATION

[i] Going concern

These Interim Consolidated Financial Statements have been prepared on a going concern basis which presumes that the Company will continue in operation for the foreseeable future and will be able to realize assets and discharge liabilities in the normal course of its operations.

As of June 30, 2021, the Company had working capital of \$9,815 (negative working capital December 31, 2020 – \$21,997) and an accumulated deficit of \$456,501 (December 31, 2020 - \$436,559). During the six months ended June 30, 2021, the Company used cash in operating activities of \$11,336 (six months ended June 30, 2020 - \$21,382) resulting primarily from the loss from operations \$14,973 (six months ended June 30, 2020 - \$25,139) offset by items not affecting cash such as depreciation, amortization and stock based compensation. The Company has insufficient cash on hand to fund its planned operations, including debt repayments for the next twelve months (see note 16). The Company's ability to continue as a going concern is dependent upon its ability to generate sufficient revenues and positive cash flows from its operating activities and/or obtain sufficient funding to meet its obligations.

The Company may need to reschedule its current debt obligations or obtain further funding in the form of asset sales, debt, equity or a combination thereof to continue operations for the next twelve months. There can be no assurance that the existing debt obligations will be rescheduled or that additional funding will be available to the Company, or, if available, that this funding will be on acceptable terms. If positive operating cash flows are not achieved, debt obligations are not repaid, rescheduled or adequate funding is not available, the Company may be required to delay or reduce the scope of any or all of

(*Unaudited*)

(expressed in thousands of Canadian Dollars except as otherwise indicated)

its projects. These conditions indicate the existence of a material uncertainty that may cast significant doubt about the Company's ability to continue as a going concern.

These Interim Consolidated Financial Statements do not reflect adjustments that would be necessary if the going concern assumption were not appropriate. Should the Company be unable to generate sufficient cash flow from operating and/or financing activities, the carrying value of the Company's assets could be subject to material adjustments and other adjustments may be necessary to these financial statements should such events impair the Company's ability to continue as a going concern.

On August 10, 2021, the Company's Revolving Facility lender provided a further \$3,000 advance to the Company under the current facility which matures on December 31, 2021.

[ii] Interim Financial Reporting

These Interim Consolidated Financial Statements have been prepared by management in accordance with International Accounting Standard ("IAS") 34, "Interim Financial Reporting" as issued by the International Accounting Standards Board ("IASB"). The same accounting policies and methods of computation were followed in the preparation of these Interim Consolidated Financial Statements as those disclosed in the Company's annual audited consolidated financial statements for the year ended December 31, 2020, with the exception of the new accounting policy adopted by the Company (see note 3(i)).

These Interim Consolidated Financial Statements do not include all of the information required for full annual consolidated financial statements and accordingly should be read in conjunction with the annual audited consolidated financial statements for the year ended December 31, 2020 which are made available on SEDAR at www.sedar.com.

These Interim Consolidated Financial Statements were approved by the Board of Directors of the Company and authorized for issue by the Board of Directors of the Company on August 11, 2021.

(Unaudited)

(expressed in thousands of Canadian Dollars except as otherwise indicated)

3. SIGNIFICANT ACCOUNTING POLICIES

The preparation of these Interim Consolidated Financial Statements requires the use of certain critical accounting estimates. It also requires management to exercise judgement in applying the Company's accounting policies. The areas involving a higher degree of judgement or complexity, or areas where assumptions and estimates are significant to the Interim Consolidated Financial Statements are consistent with those disclosed in the notes to the annual consolidated financial statements for the year ended December 31, 2020, except as noted below.

[i] New accounting policies adopted by the Company

Non-current assets (or disposal groups) held for sale

Non-current assets (or disposal groups) are classified as held for sale if their carrying amount will be recovered principally through a sale transaction rather than through continuing use. Assets held for sale are measured at each reporting period at the lower of their carrying amount and fair value less costs to sell ("FVLCS"), except for inventories, biological assets, deferred tax assets, assets arising from employee benefits, financial assets and investment property that are carried at fair value and contractual rights under insurance contracts, which are measured in accordance with the Company's other accounting policies, as applicable.

An impairment loss is recognized for any initial or subsequent write-down of the assets held for sale (or disposal group) to FVLCS. A gain is recognized for any subsequent increases in FVLCS of assets held for sale (or disposal group), but not in excess of any cumulative impairment loss previously recognized. A gain or loss not previously recognized by the date of the sale of the non-current assets (or disposal group) is recognized at the date of derecognition.

Non-current assets (including those part of a disposal group) are not depreciated or amortized while they are classified as held for sale. Interest and other expenses attributable to the liabilities of a disposal group classified as held for sale continue to be recognized.

Non-current assets classified as held for sale are presented separately from the other assets in the balance sheet. The liabilities of a disposal group classified as held for sale are presented separately from other liabilities in the balance sheet.

(Unaudited)

(expressed in thousands of Canadian Dollars except as otherwise indicated)

4. SEGMENTED INFORMATION

The Company's business activities are conducted through one reportable operating segment which consists of the production and distribution of cannabis, hemp and their related products which reports to one chief decision maker, the Company's CEO. Segment performance is based by region. The Company's Canadian and European operating segments are aggregated into one reportable segment based on similarities in the nature of their products and types of customers. The North American region is comprised primarily of the Company's operations and assets in Canada which is the country in which the Company is domiciled.

[i] Revenue, gross profit and select expenses by region is as follows

For the three months ended June 30, 2021, the Company had one customer that accounted for 45% of total revenue (three months ended June 30, 2020 – one customer accounted for 28% of total revenue). For the six months ended June 30, 2021, the Company had one customer that accounted for 44% of total revenue (six months ended June 30, 2020 – one customer accounted for 17% of total revenue).

	For the three months ended June 30, 2021					For the six months ended June 30, 2021					
	North America		Europe		Total		North America		Europe		Total
Revenue	\$ 10,400	\$	1,416	\$	11,816	\$	17,068	\$	3,730	\$	20,798
Gross profit	\$ 2,488	\$_	691	\$	3,179	\$	4,320	\$	1,989	\$	6,309
Operating expenses, excluding stock-based compensation, depreciation and amortization	\$ 6,252	\$	1,009	\$	7,261	\$	11,385	\$	2,299	\$	13,684
Share based compensation	\$ 1,019	\$_		\$	1,019	\$	1,632	\$		\$	1,632
Depreciation and amortization	\$ 3,546	\$	433	\$	3,979	\$	5,049	\$	917	\$	5,966
Loss on assets held for sale	\$ (17,688)	\$_		\$	(17,688)	\$	(17,688)	\$		\$	(17,688)
Impairment reversal for non-financial assets	\$ 	\$_		\$		\$	21,811	\$		\$	21,811
Other non-operating income (expense) (excluding impairment and loss on assets held for sale)	\$ (6,061)	\$	185	\$	(5,876)	\$	(9,978)	\$	668	\$	(9,310)
		_			(22.400)		(10 -01)				(20.04=)
Net loss	\$ (32,078)	\$_	(402)	\$	(32,480)	\$	(19,601)	\$	(416)	\$	(20,017)

(Unaudited)

(expressed in thousands of Canadian Dollars except as otherwise indicated)

	For the three months ended June 30, 2020				For the	x months ended ne 30, 2020	i
	North America	Europe	Total		North America	Europe	Total
Revenue	\$ 2,713 \$	2,112\$	4,825	\$	3,377	\$ 4,507 \$	7,884
Gross profit	\$ 237\$	1,089\$	1,326	\$	458	\$ 2,574 \$	3,032
Operating expenses, excluding stock-based compensation, depreciation and amortization	\$ 6,740\$	1,529\$	8,269	\$	17,414	\$ 3,630 \$	21,044
Share based compensation	\$ 1,657\$	<u> </u>	1,657	\$	4,127	\$ \$	4,127
Depreciation and amortization	\$ 912\$	369\$	1,281	\$	2,087	\$ 913 \$	3,000
Impairment of investment in associates	\$ <u> </u>	<u> </u>		\$	(3,082)	\$ \$	(3,082)
Impairment charge for non-financial assets	\$ <u> </u>	<u> </u>		\$	(52,765)	\$ \$	(52,765)
Other non-operating income (expense) (excluding impairment)	\$ (268)\$	159\$	(109)	\$	(2,084)	\$ (418) \$	(2,502)
Net loss	\$ (9,340)\$	(435)\$	(9,775)	\$	(81,102)	\$ (2,109) \$	(83,211)

[ii] Property, plant and equipment, net is domiciled as follows

	_	June 30, 2021	December 31, 2020
North America	\$	112,883	\$ 142,612
Europe		3,750	4,651
	\$	116,633	\$ 147,263

[iii] Intangible assets and goodwill, net are domiciled as follows

	J	une 30, 2021	 December 31, 2020
North America	\$	6,171	\$ 2,383
Europe		5,697	6,550
	\$	11,868	\$ 8,933

5. SALE OF VALLEYFIELD ASSETS

On June 22, 2021, the Company completed the sale of the majority of its assets in Valleyfield, Quebec, including all of the industrial and agricultural land, main hybrid greenhouse, rooftop greenhouse, all support buildings and certain related equipment (the "Valleyfield Assets") for gross proceeds of \$27,000 (net proceeds of \$25,512).

The following is a continuity of the Company's assets held for sale, which comprise entirely of the Valleyfield Assets:

	Valleyfield Assets
Balance, December 31, 2020	\$ _
Transferred from property, plant and equipment	43,200
Remeasurement of assets held for sale	(17,688)
Gross proceeds on sale	(27,000)
Transaction costs	1,488
Balance, June 30, 2021	_

The Company was also refunded the deposit that it had with Hydro-Quebec, including interest, of \$5,761, see Note 11 – Other Assets. Concurrent with the transaction, the Company repaid the remaining principal balance to its senior secured first lien credit facility (the "Senior Loan"), including a 2% prepayment penalty, to settle all of its outstanding obligations and

(*Unaudited*)

(expressed in thousands of Canadian Dollars except as otherwise indicated)

terminated the loan agreement with such lender, see Note 6 – Loans.

As also agreed to with the purchaser of the Valleyfield Assets, the Company entered into a lease with such purchaser concurrent with the closing of the transaction, for approximately 80,000 square feet of cultivation and processing space in the Quebec Facility, see Note 12 – Leases.

6. LOANS

The following tables illustrate the continuity schedule and presentation of the Company's loans:

	For the six months ended June 30, 2021	For the year-ended December 31, 2020
Opening Balance	\$ 40,755	\$ 17,433
Additions	_	24,658
Deferred financing fee	_	(3,044)
Residual fair value of equity portion	_	(1,628)
Accretion	4,853	4,199
Debt modification	_	(799)
Principal payments	(32,200)	(500)
Effects of movements in foreign exchange	(22)	(19)
Change in balance of Revolver Loan	2,346	455
Ending Balance	\$ 15,732	\$ 40,755

	June	30, 2021	December 31, 2020
Loans	\$	15,732 \$	40,755
Current portion		(15,732)	(40,755)
Long term portion	\$	<u> </u>	<u> </u>

Senior secured credit facility

On December 24, 2019, the Company closed a Senior Loan with a commercial lender with first security rights on the Company's assets, primarily its production facilities. Under the Senior Loan the Company received gross proceeds of \$32,700 from the lender at a thirteen percent (13%) rate of interest. Per the Senior Loan agreement, there were no scheduled principal repayments required for the first twelve months of the term of the Senior Loan and after which the Company was required to make monthly repayments commencing on January 1, 2021 plus interest, with the remaining unpaid balance upon maturity which was expected on December 15, 2021. The Senior Loan carried a prepayment option at any time with a 2% prepayment premium on the outstanding principal of the Senior Loan.

On June 27, 2021, the Company repaid the remaining principal of \$30,977 concurrent with the sale of its Valleyfield Assets and a 2% prepayment premium of \$620, recorded in finance costs. The Company settled all obligations as a result and terminated the loan agreement with such lender.

Revolver Loan

On April 22, 2020, the Company closed a revolving secured second lien credit facility (the "Revolver Loan") with a commercial lender for gross proceeds of up to \$30,000 of which \$10,000 was funded on April 22, 2020 and carries a conventional competitive rate. The Revolver Loan was secured by a second lien over the assets of the Company with a first lien over substantially all of the cannabis and cannabis derived inventory and Canadian trade receivables. As the accounts receivable balance eligible for collateral increases, additional credit is available to the Company up to a maximum of an additional \$20,000. The Revolver Loan matures on December 31, 2021.

In conjunction with the Valleyfield Asset sale, the lender for the Revolver Loan agreed to release its second lien security on the Valleyfield Assets and with the settlement of the Senior Loan described above, holds first security on the Company's Hamilton Facility with all other terms and conditions still in place.

As at June 30, 2021, the total principal balance outstanding related to the Revolver Loan was \$15,801. The Revolver Loan

(Unaudited)

(expressed in thousands of Canadian Dollars except as otherwise indicated)

has several covenants which the Company had met as at June 30, 2021.

On August 10, 2021, the Company's Revolving Facility lender provided a further \$3,000 advance to the Company under the current facility which matures on December 31, 2021.

HemPoland Loan

The Company assumed a loan payable on certain premises in Poland ("HemPoland Loan") on the acquisition of its wholly owned subsidiary HemPoland on October 1, 2018. As at June 30, 2021, the total principal balance outstanding related to the HemPoland Loan was \$486.

(Unaudited)

(expressed in thousands of Canadian Dollars except as otherwise indicated)

7. PROPERTY, PLANT AND EQUIPMENT

Cost:	Lai	nd	Buildings	rniture and xtures		oduction Juipment	in	Building nprovements	omputer uipment	Au	tomobiles		onstruction progress	Ri	ight-of-use assets	Total
Balance, December 31, 2020	\$ 6,	855	\$ 61,205	\$ 390	\$	65,714	\$	698	\$ 1,352	\$	366	\$	250,019	\$	7,273	\$ 393,872
Transfers		_	5,037	_		1,473		_	_		_		(6,510)		_	_
Additions		_	<u> </u>	_		73		_	_		38		57		86	254
Disposals		_	_	_		_		_	_		(16)		(2,782)		(323)	(3,121)
Derecognition on investment in join venture	nt	_	_	_		(683)		_	_		_		_		_	(683)
Reclassification to assets held for sale	Note 5 (4,	080)	(1,472)	(14)		(244)		(37)	_		_		(240,784)		_	(246,631)
Effects of movements in foreign exchange and other		_	(119)	(9)		(87)		_	(2)		(6)				(161)	(384)
Balance, March 31, 2021	\$ 2,	775	\$ 64,651	\$ 367	\$	66,246	\$	661	\$ 1,350	\$	382	\$	_	\$	6,875	\$ 143,307
Transfers		_	_	_		_		_			_		_		_	_
Additions		_	_	_		29		_	_		_		_		1,882	1,911
Disposals		_	_	_		(456)		_	_		(35)		_		(69)	(560)
Effects of movements in foreign exchange and other		_	49	4		36		_	1		2		_		64	156
Balance, June 30, 2021	\$ 2,	775	\$ 64,700	\$ 371	\$	65,855	\$	661	\$ 1,351	\$	349	\$		\$	8,752	\$ 144,814
Accumulated depreciation and impairment:					4											
Balance, December 31, 2020	\$	_	\$ 40,061	\$ 236	\$	42,479	\$	504	\$ 1,097	\$	277	\$	160,484	\$	1,471	\$ 246,609
Transfers		_	2,014	_		42		_	_				(2,056)		_	
Depreciation		_	250	6		1,128		4	21		5		(4.005)		233	1,647
Disposals		_	_	_		_		-	_		_		(1,806)		(323)	(2,129)
Derecognition on investment in join venture	nt	-	_	_		(52)		_	_		_		_		_	(52)
Reversal of impairment		_	(34,632)	(79)		(27,771)		(109)	(401)		(56)		45,283		_	(17,765)
Reclassification to assets held for sale	Note 5	-	(1,274)	(13)		(207)		(33)	_		_		(201,904)		_	(203,431)
Effects of movements in foreign exchange and other		_	(7)	 (2)		(28)		_	(1)		(1)		(1)		(61)	(101)
Balance, March 31, 2021	\$	_	\$ 6,412	\$ 148	\$	15,591	\$	366	\$ 716	\$	225	\$		\$	1,320	\$ 24,778
Transfers		_	_	_		_		_	_		_		_		_	_
Depreciation		_	703	9		2,549		9	53		10		_		196	3,529
Disposals		_	_	_		(115)		_	_		(1)		_		(52)	(168)
Effects of movements in foreign exchange and other		_	3	1		12	_		2		_	_	_		24	42
Balance, June 30, 2021	\$	_	\$ 7,118	\$ 158	\$	18,037	\$	375	\$ 771	\$	234	\$		\$	1,488	\$ 28,181
Net book value, June 30, 2021	\$ 2,	775	\$ 57,582	\$ 213	\$	47,818	\$	286	\$ 580	\$	115	\$	_	\$	7,264	\$ 116,633

(Unaudited)

(expressed in thousands of Canadian Dollars except as otherwise indicated)

As a result of the reclassification of the Valleyfield Assets held for sale, the Company performed an impairment analysis as at March 31, 2021 on its cannabis related activities from production in Canada (the Canadian cash generating unit ("Canadian CGU")). As a result of this impairment assessment, the Company determined that the Valleyfield Assets met the criteria to be tested for impairment separately from the Canadian CGU. The Company tested the Valleyfield Assets for impairment first, then subsequently tested the Canadian CGU for an impairment reversal. The Company recognized a \$46,475 impairment loss at March 31, 2021 associated with the Valleyfield Assets recognized in property, plant and equipment, and a \$68,286 reversal of previously recognized impairment losses on the Canadian CGU of which \$64,240 was allocated to property, plant and equipment and \$4,046 allocated to intangible assets (note 8). The net impact to property, plant and equipment was a reversal of impairment of \$17,765. As a result of the impairment analysis, the Canadian CGU yielded a higher recoverable amount in comparison to its applicable carrying value. The recoverable amount of the Canadian CGU was based on its value in use, which was determined to be greater than its fair value less costs of disposal, and resulted in a reversal of previously recognized impairment losses. The Canadian CGU's value in use was estimated by discounting the probability weighted future cash flows expected to be generated from the continuing use of the Canadian CGU using level 3 inputs. The significant assumptions applied in the determination of the recoverable amount were materiality consistent with the impairment analysis performed as at December 31, 2020, including a discount rate of 16.5%, with the exception of the inclusion of the expected proceeds from the assets held for sale, partially offset by certain newly expected operating costs to be incurred by the Canadian CGU over the period of the forecast (impairment charge for the three and six months en

(Unaudited)

(expressed in thousands of Canadian Dollars except as otherwise indicated)

8. INTANGIBLE ASSETS

A continuity of the intangible assets is as follows:

	C	lealth anada icence		chnology icences	We	ebsite		stribution Channels]	Brands	a 	Other equired rights		Total
Cost:	ф	5.05 0	ф	2.065	ф	400	ф	5 0.00	ф	1.040	ф	1 200	ф	17 (10
Balance, December 31, 2020 Transfers	\$	5,870	\$	3,065 61	\$	400	\$	5,869	\$	1,048	\$	1,388	\$	17,640
		_		01		_		_		_		(61)		_
Effect of movements in foreign exchange				(37)				(305)		(55)		(68)		(465)
Balance, March 31, 2021	\$	5,870	\$	3,089	\$	400	\$	5,564	\$	993	\$	1,259	\$	17,175
Additions		_		6		_		_		_		_		6
Effect of movements in foreign				15				(5)		(1)		(1)		8
exchange								(5)		(1)		(1)		
Balance, June 30, 2021	\$	5,870	\$	3,110	\$	400	\$	5,559	\$	992	\$	1,258	\$	17,189
Accumulated amortization and impairment:														
Balance, December 31, 2020	\$	4,262	\$	2,106	\$	297	\$	943	\$	169	\$	930	\$	8,707
Amortization for the period		25		84		6		105		19		101		340
Reversal of impairment		(2,770)		(1,105)		(171)		_		_		_		(4,046)
Effect of movements in foreign exchange		_		(15)		_		(55)		(10)		(53)		(133)
Balance, March 31, 2021	\$	1,517	\$	1,070	\$	132	\$	993	\$	178	\$	978	\$	4,868
Amortization for the period		70		150		16		100		18		96		450
Effect of movements in foreign exchange		_		6		_		(1)		_		(2)		3
Balance, June 30, 2021	\$	1,587	\$	1,226	\$	148	\$	1,092	\$	196	\$	1,072	\$	5,321
,	<u> </u>				<u> </u>				Ť		Ť			
Net book value, June 30, 2021	\$	4,283	\$	1,884	\$	252	\$	4,467	\$	796	\$	186	\$	11,868

As a result of the impairment assessment described in note 7, \$4,046 impairment was reversed during the six months ended June 30, 2021, (three and six months ended June 30, 2020 - \$nil and \$1,040 impairment loss, respectively).

(*Unaudited*)

(expressed in thousands of Canadian Dollars except as otherwise indicated)

9. BIOLOGICAL ASSETS

As at June 30, 2021, the Company's biological assets consisted of cannabis seeds and cannabis plants. The continuity of the Company's biological assets is as follows:

	Capitalized cost		Biological asset fair value adjustment		Amount
Balance, December 31, 2020	\$ 1,374	\$	610	\$	1,984
Unrealized gain on changes in fair value of biological assets	_		5,565		5,565
Production costs capitalized	3,637		_		3,637
Transfer to inventory upon harvest	(3,441))	(5,093))	(8,534)
Balance, June 30, 2021	\$ 1,570	\$	1,082	\$	2,652

The Company measures its biological assets at their fair values less estimated costs to sell. This is determined using a model which estimates the expected harvest yields in grams for plants currently being cultivated, and then adjusts that amount for the expected selling price per gram, waste and also for any additional costs to be incurred, such as post-harvest cost.

The following significant unobservable inputs, all of which are classified as level three on the fair value hierarchy, were used by management as part of this model:

- Estimated selling price per gram calculated as the expected approximate future per gram selling prices of the Company's cannabis products.
- Stage of growth represents the weighted average number of weeks out of the estimated week growing cycle that biological assets have reached as of the measurement date based on historical experience. The Company accretes fair value on a straight-line basis according to the stage of growth and estimated costs to complete cultivation.
- Yield by plant represents the expected number of grams of finished cannabis inventory which are expected to be obtained from each harvested cannabis plant based on historical experience.

The inter-relationship between these aforementioned unobservable inputs and the fair-value of the biological assets is such that the carrying value of the biological assets as at June 30, 2021 and December 31, 2020 would increase (decrease) if any of these inputs were to be higher (lower).

Other unobservable, level three inputs into the biological asset model include estimated post harvest costs, costs to complete and wastage. These additional level three inputs are not considered to be significant.

The following table quantifies each significant unobservable input, and provides the impact of a 10% increase or decrease in each input would have on the fair value of biological assets:

	As at June 30, 2021	As at December 31, 2020	Impact of 10% change as at June 30, 2021	change as at December 31,
Estimated net selling price per gram (1)	\$2.19 to \$6.06	\$2.19 to \$6.06	\$ 646	\$ 503
Estimated stage of growth	7 to 8 weeks	7 to 8 weeks	\$ 682	\$ 552
Estimated yield of agricultural produce by plant (2)	73 to 111 grams	52 to 100 grams	\$ 305	\$ 241

- (1) The estimated net selling prices per gram is based on the negotiated distribution selling prices which exclude duties.
- (2) The estimated yield varies based on the Company's different cannabis strains.

The Company's estimates are, by their nature, subject to change. Changes in the significant assumptions described will be reflected in future changes in the gain or loss on biological assets. There were no changes between fair value hierarchy levels.

(Unaudited)

(expressed in thousands of Canadian Dollars except as otherwise indicated)

10. INVENTORY

The Company's inventory assets include the following as of June 30, 2021 and December 31, 2020:

	cam	annabis and nabis derived products	Hemp and hemp derived products	As at June 30, 2021
Raw Materials and Packaging	\$	2,628 \$	1,021	\$ 3,649
Work-in-progress		12,780	2,395	15,175
Finished Goods		1,230	673	1,903
Total Inventory	\$	16,638 \$	4,089	\$ 20,727
		nnabis and nabis derived	Hemp and hemp	As at

	cannabis derived products	Hemp and hemp derived products	As at
Raw Materials and Packaging	\$ 2,614	\$ 1,589	\$ 4,203
Work-in-progress	7,561	2,152	9,713
Finished Goods	2,424	795	3,219
Total Inventory	\$ 12,599	\$ 4,536	\$ 17,135

During the three and six months ended June 30, 2021, inventories expensed directly to cost of sales were \$3,729 and \$6,900, respectively (three and six months ended June 30, 2020 - \$3,881 and \$4,903, respectively).

11. OTHER ASSETS

A summary of other assets is presented as follows:

	Additional Reference	As at June 30, 2021	As at December 31, 2020
Deposit per Hydro-Quebec contribution agreement	11 [a]	_	5,681
Investment in Califormulations	11 [b]	_	1,272
Term deposits held as letter of credit collateral	16,17	935	935
Term deposits not held as letter of credit collateral		100	100
Other		4,209	3,864
		5,244	11,852
Less: Current portion		(1,392)	(853)
		3,852	10,999

[a] Deposit per Hydro-Quebec Contribution Agreement

On June 22, 2021, in conjunction with the sale of the Company's Valleyfield Assets, the Company was refunded its deposit with Hydro Quebec of \$5,761, including interest accrued of \$80.

[b] Investment in Califormulations

On March 29th, 2021, the Company sold its investment in Califormulations, LLC for \$1,242 (US\$1 million).

(*Unaudited*)

(expressed in thousands of Canadian Dollars except as otherwise indicated)

12. LEASES

Below is a summary of the activity related to the Company's lease liabilities:

	For the six months ended June 30, 2021	For the end Decemi 20	led ber 31,
Opening Balance	\$ 5,570	\$	3,545
Additions	1,968		2,889
Interest on lease liabilities	254		494
Interest payments on lease liabilities	(254)		(494)
Principal payments on lease liabilities	(298)		(525)
Extinguishment of lease liabilities	(34)		(315)
Foreign exchange differences	(61)		(24)
Closing Balance	\$ 7,145	\$	5,570
Current portion lease liabilities	\$ 2,000	\$	1,019
Long-term portion lease liabilities	\$ 5,145	\$	4,551

Valleyfield Lease

In conjunction with the sale of the Company's Valleyfield Assets, the Company entered into a two-year lease for 80,000 square feet, representing cultivation, processing and manufacturing spaces in the Quebec Facility.

13. SHARE CAPITAL

Issued capital

- i. During the six months ended June 30, 2021, a total of 15,414,958 common shares of the Company were issued under its at-the-market Prospectus Supplement dated December 2, 2020 for gross proceeds of \$8,281 (net proceeds of \$8,032).
- ii. During the six months ended June 30, 2021, a total of 24,198,600 common shares of the Company were issued as a result of 24,198,600 previously issued and outstanding warrants of the Company that were exercised at a weighted average exercise price of \$0.31 per warrant, for aggregate gross proceeds of \$7,560. During the six months ended June 30, 2020, a total of 500,500 common shares of the Company were issued as a result of previously issued and outstanding warrants of the Company that were exercised at a weighted average exercise price of \$0.38 per option, for aggregate gross proceeds of \$191.
- iii. During the six months ended June 30, 2021, a total of 1,262,903 common shares of the Company were issued as a result of 1,262,903 previously issued and outstanding equity settled restricted share units ("RSUs") of the Company that were previously issued at a weighted average fair value of \$0.38 per RSU. There are no proceeds related to the exercise of RSUs.
- iv. During the six months ended June 30, 2021, a total of 1,591,535 common shares of the Company were issued to settle severance owing of \$404 to a former employee.

14. CONTRIBUTED SURPLUS

[a] Share based payments

For the three and six months ended June 30, 2021, the Company recorded \$852 and \$1,396, respectively, in non-cash share-based compensation expense pursuant to the grant of stock options (three and six months ended June 30, 2020 - \$1,442 and \$3,595, respectively).

(Unaudited)

(expressed in thousands of Canadian Dollars except as otherwise indicated)

The following is a summary of the changes in the Company's Employee Stock Option Plan options:

	For the six mo June 30,		For the year ended December 31, 2020			
	Number of Options	Weighted Average Exercise Price	Number of Options	Weighted Average Exercise Price		
Outstanding - beginning of period	24,339,401	1.74	17,897,599	3.24		
Granted	6,599,000	0.31	15,021,000	0.31		
Exercised	-	-	(847,600)	0.50		
Cancelled/Expired	(6,464,402)	2.73	(7,731,598)	2.58		
Outstanding, end of period	24,473,999	1.09	24,339,401	1.74		
Exercisable, end of period	7.387.311	2.00	5,663,387	3.82		

Grant date	Options Outstanding #	Options Exercisable #	Exercise Price \$	Weighted Average remaining contractual life of outstanding options in years
June 25, 2018 - December 14, 2018	1,040,000	720,001	\$3.08 - \$6.91	1.99 - 2.46
January 8, 2019 - August 21, 2019	3,551,333	2,237,322	\$2.67 - \$5.13	2.53 - 3.15
November 18, 2019	687,666	231,660	\$0.83	3.39
March 13, 2020 - December 21, 2020	12,751,000	4,198,328	\$0.26 - \$0.51	3.70 - 4.48
March 12, 2021 - June 29, 2021	6,444,000	-	\$0.30 - \$0.36	4.70 - 5.00
Balance, June 30, 2021	24,473,999	7,387,311		4.11

In determining the amount of share-based compensation, the Company uses the Black-Scholes option pricing model to establish the fair value as at the grant date of options granted. Stock options granted during the respective periods highlighted below were fair valued based on the following weighted average assumptions:

	Averages for the three months ended June 30, 2021	Averages for the year ended December 31, 2020
Risk-free interest rate	0.55%	0.36%
Expected dividend yield	Nil	Nil
Expected annualized volatility	85.00%	88.55%
Expected life of options (years)	3.49	3.70
Black-Scholes value of each option	\$0.19	\$0.15

Volatility was estimated by using the historical volatility of the Company and other companies that the Company considers comparable that have trading and volatility history. The expected life of the options is based on historical data and current expectations and is not necessarily indicative of exercise patterns that may occur. The expected volatility reflects the assumption that the historical volatility over a period similar to the expected life of the options is indicative of future trends, which may also not necessarily be the actual outcome. The expected life in years represents the period of time that options granted are expected to be outstanding. The risk-free rate was based upon the Canada government bonds with a remaining term equal to the expected life of the options.

[b] Reserve for warrants

The following table reflects the continuity of warrants:

(Unaudited)

(expressed in thousands of Canadian Dollars except as otherwise indicated)

	Number of warrants	Weighted Average Exercise Price	Amount, net of warrant issue costs
	#	\$	\$
Balance, December 31, 2020	230,815,055	1.37	66,111
Warrants exercised in the period	(24,198,600)	0.31	(1,124)
Warrants expired in the period	(49,025,015)	4.80	(54,881)
Balance, June 30, 2021	157,591,440	0.47	10,106

As at June 30, 2021, the following warrants were outstanding:

	Exercise	
Expiry Date	Price	Number of Warrants
	\$	#
December 19, 2022	1.00	20,607,500
April 1, 2023	0.39	3,000,000
April 13, 2023	0.39	1,500,000
April 27, 2023	0.38	10,813,052
May 27, 2024	0.50	500,000
June 12, 2024	0.50	45,712,500
October 23, 2025	0.30	24,873,354
November 2, 2025	0.30	8,500,000
December 10, 2025	0.35	42,085,034
		157,591,440

[c] Restricted share units

Under the Company's, restricted share unit plan (the "RSU Plan"), RSUs may be granted up to a fixed maximum of 10,000,000 common shares, which entitle the holder to receive one common share without payment of additional consideration at the end of the restricted period, as determined by the Board of Directors at the time of the grant. The RSUs vest in tranches based on certain performance conditions being met, with share-based compensation expense being recognized from grant date to the expected performance completion date.

At June 30, 2021, 5,242,706 (December 31, 2020 – 1,243,845) shares of the Company were reserved for issuance under the RSU Plan. For the three and six months ended June 30, 2021, the Company recorded \$167 and \$236, respectively, in non-cash stock-based compensation related to RSU compensation (three and six months ended June 30, 2020 - \$207 and \$259, respectively).

	For the six mo June 30,		For the year-ended December 31, 2020		
	Number of Units	Weighted Fair Value	Number of Units	Weighted Fair Value	
Outstanding - beginning of period	1,243,845	0.33	54,348	2.76	
Granted	5,405,098	0.32	2,600,000	0.27	
Exercised	(1,262,903)	0.38	(703,837)	0.37	
Forfeited	(143,334)	0.27	(706,666)	0.27	
Outstanding, end of period	5,242,706	0.31	1,243,845	0.33	

The accounting fair value of the equity settled RSUs as at the grant date is calculated using the number of RSUs expected to be earned multiplied by the grant date fair market value of a share of the Company's stock. Each reporting period, the number of RSUs that are expected to be earned is re-determined and the "fair value" of these RSUs is amortized over the remaining requisite period less amounts previously recognized.

(*Unaudited*)

(expressed in thousands of Canadian Dollars except as otherwise indicated)

The estimated fair value of the equity settled RSUs granted during the three and six months ended June 30, 2021 was \$1,312, \$1,412, respectively, (three and six months ended June 30, 2020 \$Nil and \$703, respectively) and will be recognized as an expense over the vesting period of the RSUs.

[d] Employee Stock Purchase Plan

The Company has established an Employee Stock Purchase Plan which created a reserve of 3,000,000 common shares that may be issued from treasury. As at June 30, 2021, no securities were issued from treasury under this plan.

15. SUPPLEMENTARY CASH FLOW INFORMATION

The changes in non-cash working capital items are as follows:

	For the three months ended			ths ended	For the six months ended			
	J	une 30, 2021	Jı	une 30, 2020	June 30, 2021	June 30, 2020		
Prepaid expenses and deposits	\$	97	\$	629	\$ (109)	\$ (191)		
Refundable sales taxes receivable		203		20	(53)	6,007		
Trade receivable		(3,917)		(1,203)	889	(1,168)		
Capitalized cost of biological assets		1,425		2,284	3,245	3,382		
Inventory		(2,680)		(3,557)	(5,801)	(6,910)		
Other current assets		(152)		(129)	(171)	(237)		
Other assets		120		(534)	144	(449)		
Accounts payable and accrued liabilities		4,934		1,677	2,848	(102)		
Sales taxes payable		294		_	294	_		
Deferred revenue	_	(150)		135	(150)	135		
Total	\$	174	\$	(678)	\$ 1,136	\$ 467		

16. COMMITMENTS AND CONTINGENCIES

The Company has the following gross contractual obligations as at June 30, 2021, which are expected to be payable in the following respective periods:

	Contractual cash flows - 12 months ending							
	Carrying amount	Total	June 2022	June 2023	June 2024	June 2025	June 2026	Thereafter
	\$	\$	\$	\$	\$	\$	\$	\$
Accounts payable and accrued								
liabilities	17,317	17,317	17,317	-	-	-	-	-
Loans	15,732	17,278	17,278	-	-	-	-	-
Lease liabilities	7,145	10,444	2,039	2,002	869	828	616	4,090
Total contractual obligations	40,194	45,039	36,634	2,002	869	828	616	4,090

[a] Construction agreements

The Company entered into contracts to facilitate the construction of the Hamilton Facility with various vendors. Pursuant to some of these agreements, as at June 30, 2021, the Company has letters of credit in the amount of \$585 which may be drawn upon in the event of material breaches of the respective agreements. These letters of credit bear conventional rates of interest partially offset by the interest earned on guaranteed investment certificates ("GIC") securing the letters as collateral. The Company has pledged corresponding GICs as collateral, which has been recorded in other assets. As at June 30, 2021, there have been no material breaches as defined by the agreements and no amounts have been drawn on the letters of credit.

The Company entered into escrow agreements in prior years with its construction partners in Ontario and in Québec and as such \$219 is included in the restricted cash balance as at June 30, 2021 related to a construction partner.

(*Unaudited*)

(expressed in thousands of Canadian Dollars except as otherwise indicated)

[b] Other contractual commitments

The lease for the office space of the Company's headquarters required the issuance of a letter of credit in the amount \$350, which may be drawn upon by the landlord in the event of a material breach of the agreement. As at June 30, 2021, there have been no breaches and no amounts have been drawn upon this letter of credit.

[c] Claims and Litigation

From time to time, the Company and/or its subsidiaries may become defendants in legal actions and the Company intends to defend itself vigorously against all legal claims. The Company is subject to certain employment related claims by a former employee for which a provision in accounts payable and accrued liabilities has been recognized only to the extent that it is likely to result in future economic outflows. The Company has also been subject to a claim by former warrant holders for approximately \$1,250. No provision in relation to this claims has been recognized as the Company estimates that it is more likely than not that a present obligation does not exist that will result in a payment to be made by the Company for these claims. On August 3, 2020 the Company was named as a defendant in a litigation matter commenced in the United States District Court for the Middle District of Georgia relating to its minority investment in a US based beverage incubation business, seeking, among other things, unquantified compensatory damages and injunctive relief. No provision in relation to this claim has been recognized as the Company estimates that it is more likely than not that a present obligation does not exist that will result in a payment to be made by the Company for this claim and the Company intends to vigorously defend the matter. Other than the claims previously described, the Company is not aware of any other material or significant claims against the Company.

17. FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT

[a] Fair values

The Company's financial instruments were comprised of the following as at June 30, 2021: cash and cash equivalents; restricted cash; refundable sales taxes receivable; trade receivables; certain other current assets; accounts payable and accrued liabilities; sales taxes payable; loans and contingent consideration.

The fair values of the financial assets and financial liabilities are determined at the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced or liquidation sale. The assumption for the instruments recorded at amortized costs that the instruments' fair values approximate their carrying amounts is largely due to the short-term maturities of these instruments.

[b] Fair value hierarchy

Financial instruments recorded at fair value on the consolidated statement of financial position are classified using a fair value hierarchy that reflects the significance of the inputs used in making the measurements. The fair value hierarchy has the following levels:

- Level 1 valuation based on quoted prices (unadjusted) in active markets for identical assets or liabilities;
- Level 2 valuation techniques based on inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly (i.e., as prices) or indirectly (i.e., derived from prices); and
- Level 3 valuation techniques using inputs for the asset or liability that are not based on observable market data (unobservable inputs).

The fair value hierarchy requires the use of observable market inputs whenever such inputs exist. A financial instrument is classified to the lowest level of the hierarchy for which a significant input has been considered in measuring fair value.

During the three and six months ended June 30, 2021, there were no transfers of amounts between levels (year ended December 31, 2020 – none).

(Unaudited)

(expressed in thousands of Canadian Dollars except as otherwise indicated)

[c] Management of risks arising from financial instruments

[i] Market risk

All foreign currencies shown in this note are also presented in thousands.

Foreign currency risk

Foreign currency risk arises due to fluctuations in the fair value or cash flows of financial instruments due to changes in foreign exchange rates. As at June 30, 2021, a portion of the Company's financial assets and liabilities held in US dollars ("USD"), Polish Zloty ("PLN") and European Euros ("EUR") which consisted of cash and cash equivalents, trade receivables, accounts payable and accrued liabilities, lease liabilities, loans, and other assets. The Company's objective in managing its foreign currency risk is to minimize its net exposure to foreign currency cash flows by transacting, to the greatest extent possible, with third parties in the functional currency. The Company is exposed to currency risk in other comprehensive income, relating to foreign subsidiaries which operating in a foreign currency. The Company has not used foreign exchange contracts to hedge its exposure to foreign currency cash flows for the three months ended June 30, 2021 as management has determined that this risk is not significant at this time. The Company is exposed to unrealized foreign exchange risk through its accounts payable and accrued liabilities. As at June 30, 2021, a 10% change in the foreign exchange rate would result in an unrealized gain or loss of approximately \$162 (December 31, 2020 - \$457).

Interest rate risk

The Company's exposure to interest rate risk relates to any investments of surplus cash as the Company's debt is fixed at a prescribed rate. The Company may invest surplus cash in highly liquid investments with short terms to maturity that would accumulate interest at prevailing rates for such investments. As at June 30, 2021, the Company had term deposits of \$585 bearing interest between 0.80% and 1.00% (December 31, 2020 - \$585, bearing interest between 0.80% and 1.00%). The Company also has \$219 in restricted cash held in trust related to the Quebec Facility construction projects and earning a conventional rate of interest from a reputable top tier Canadian bank as well as \$498 of restricted cash in a separate account related to the Revolver Loan.

[ii] Credit risk

Credit risk is the risk of financial loss to the Company if a counterparty to a financial instrument fails to meet its contractual obligations. The Company is exposed to credit-related losses in the event of non-performance by the counterparties.

The carrying amount of cash and cash equivalents, trade receivables, refundable sales taxes receivable, prepaid expenses and deposits, and other assets represents the maximum exposure to credit risk as at June 30, 2021. The objective of managing counterparty credit risk is to prevent losses in financial assets. The Company assesses the credit quality of the counterparties, taking into account their financial position, past experience and other factors. Credit risk is mitigated by entering into sales contracts with stable, creditworthy parties and through frequent reviews of exposures to individual entities.

The Company assesses the credit risk of trade receivables by evaluating the aging of trade receivables based on the invoice date and credit worthiness. The carrying amount of trade receivables is reduced through the use of an allowance account and the amount of the loss is recognized in the interim consolidated statements of income (loss) and comprehensive income (loss). When a trade receivable balance is considered uncollectible, it is written off against the allowance for expected credit losses. Subsequent recoveries of amounts previously written off are credited against operating expenses in the consolidated statements of income (loss) and comprehensive income (loss). As at June 30, 2021, the Company's trade receivables are primarily concentrated in Canada in the amount of \$8,728 with the exception of \$406 in Europe. The Company had two customers whose balances individually were greater than 10% of total trade receivables as at June 30, 2021 (December 31, 2020 – two customers).

The following tables set forth details of trade receivables, including aging of trade receivables that are not overdue, as well as an analysis of overdue amounts and related allowance for doubtful accounts:

(Unaudited)

(expressed in thousands of Canadian Dollars except as otherwise indicated)

	June 30, 2021	December 31, 2020
	\$	\$
Total trade receivables	9,159	10,023
Less allowance for expected credit losses	(25)	
Total trade receivables, net	9,134	10,023
Of which		
Current	7,291	6,182
31-90 days	1,811	3,784
Over 90 days	57	57
Less allowance for expected credit losses	(25)	
Total trade receivables, net	9,134	10,023

[iii] Liquidity risk

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they become due. The Company manages its liquidity risk by reviewing on an ongoing basis its capital requirements in relation to its current cash balances, maturity schedules and internal budgets. Refer to Note 16 – Commitments and Contingencies.

18. CAPITAL MANAGEMENT

The Company's objective is to maintain sufficient capital base to maintain investor, creditor and supplier confidence and to sustain future development of the business and provide the ability to continue as a going concern (See Note 2[i] – Going Concern). Management defines capital as the Company's shareholders' equity and loans. The Board of Directors of the Company does not establish quantitative return on capital criteria for management but rather promotes year over year sustainable profitable growth. The Company currently has not paid any dividends to its shareholders. As at June 30, 2021, total managed capital was comprised of share capital and loans of \$501,706 (December 31, 2020 - \$509,134), contributed surplus of \$108,803 (December 31, 2020 - \$108,874), and reserve for foreign currency translations of \$1,089 (December 31, 2020 – \$255). There were no changes in the Company's approach to capital management during the three and six months ended June 30, 2021 (three and six months ended June 30, 2020 – no changes).

19. OPERATING EXPENSES

The following table presents share-based compensation, depreciation and amortization by function:

	For the three months ended			For the six months ended		
	June 30, 2021	June 30, 2020		June 30, 2021	June 30, 2020	
Cost of sales related to inventory production	\$ 2,930 \$	958	\$	4,410 \$	2,270	
Sales and marketing expenses	330	284		503	692	
Research and development expenses	148	169		227	414	
General and administrative expenses	1,590	1,527		2,458	3,751	